CJC-1295 ipamorelin news this quarter changes the paperwork and sport conversation more than the treatment evidence. WADA published its 2027 list, regulators questioned online peptide sales, and a new review examined the research. It was a quiet quarter for new human treatment data: the fresh review did not test the pair in people.
As of October 1, 2026, the day this article was written, CJC-1295 and ipamorelin are not FDA-approved, and neither is the compounded combination. The dated developments below cover July through September; their meaning depends on which molecule and product they concern.
Changelog
September 21, 2026 — WADA published its 2027 Prohibited List. The World Anti-Doping Agency's announcement sets January 1, 2027 as the start date. Its S2.2.4 wording separates the molecules: CJC-1295 appears under “growth hormone-releasing hormone (GHRH) and its analogues”; ipamorelin appears under “growth hormone secretagogues (GHS) and their mimetics.” Those mean copies of a hormone-release signal and compounds that prompt hormone release, respectively.
Both remain prohibited during and outside competition, as they were on the 2026 list. This is a new edition, not a new placement for either peptide. The 2027 WADA explainer covers the wider changes. A prescription alone does not create a sport exemption.
September 4, 2026 — Argentina expanded an online-product alert. ANMAT, Argentina's medicines regulator, named Ipamorelin/CJC-1295 among unauthorized injectable products sold online. It said their manufacturers, composition and production conditions were unknown. That describes products in Argentina, not a change to U.S. prescribing rules.
August 24, 2026 — an FDA warning letter named an ipamorelin blend. The letter, posted September 1, followed a July website review. FDA identified a tesamorelin/ipamorelin blend among products sold as unapproved drugs. The letter did not name CJC-1295. It concerned the seller's products and claims, rather than announcing a new decision on the CJC-1295/ipamorelin pair.
August 19, 2026 — Colombia issued a separate product alert. INVIMA's Alert 252-2026 named ipamorelin and CJC-1295 among an online brand's products lacking Colombian registration. Like Argentina's notice, this was a local product action. It was not a U.S. drug decision or a trial result.
August 11, 2026 — a sports-medicine review mapped the evidence. Tewari and colleagues, in The American Journal of Sports Medicine, examined six compounds, including CJC-1295 and ipamorelin. About two thirds of the publications used animal models: 67% across the whole group, not a percentage for this blend. A scoping review maps existing studies. It does not enroll new patients. The authors found that current human trials did not substantiate the claimed recovery and performance benefits.
What the CJC-1295 ipamorelin news leaves unchanged
These are two peptides, short chains of protein building blocks, studied for stimulating the body's growth-hormone release. CJC-1295 resembles the GHRH signal. Ipamorelin acts through the ghrelin receptor, a cell switch normally activated by a hormone involved in hunger. Neither supplies growth hormone directly.
Their separate study records answer different questions. The 1999 ipamorelin volunteer experiment, in Pharmaceutical Research, measured drug levels and hormone release in healthy men. The 2014 hospital trial, in the International Journal of Colorectal Disease, tested gut recovery after bowel surgery. It did not find a significant improvement in its main outcome.
Neither study tested the combination. The CJC-1295/ipamorelin evidence guide explains what the component studies measured. A new review of those studies does not establish a sleep, muscle or recovery result for the pair.
Names also matter. DAC, or drug affinity complex, is an attachment that lets one CJC-1295 form bind a blood protein and persist longer. The no-DAC naming guide explains why findings cannot travel between forms just because both use the CJC name.
Where each molecule stands with FDA
As of October 1, 2026, the day this article was written, FDA's current 503A nominations PDF reads “Updated May 14, 2026.” Section 503A is the framework for traditional patient-specific compounding. Neither CJC-1295 nor ipamorelin appears in the PDF's three categories. That May date is older than this quarter.
FDA's separate safety page reads “Content current as of: 04/22/2026.” Its records differ:
| Molecule | Where FDA places it on that page |
|---|---|
| CJC-1295 | Nominated-but-withdrawn table |
| Ipamorelin acetate | Withdrawn table and active Category 2 under 503B |
Acetate identifies a salt form of ipamorelin. Section 503B concerns outsourcing facilities, a different compounding setting. Category 2 identifies potential significant safety concerns under FDA's interim policy. A withdrawn nomination means the applicant withdrew the request; it does not mean FDA declared the ingredient safe.
The CJC-1295 FDA review history explains its withdrawn nominations and earlier committee review. Compounded means a pharmacy prepares medication for an individual prescription. CJC-1295 and ipamorelin are not FDA-approved, and the compounded formulation offered here is not FDA-approved. Promise offers CJC-1295 / ipamorelin by prescription, after a licensed provider reviews your request. A licensed provider may still prescribe a compounded formulation; that decision is between you and your doctor.
What the notices mean for a medical conversation
The practical difference is accountability. A prescribed route identifies the reviewing clinician and the licensed U.S. dispensing pharmacy. It provides a record of the formulation and lot, plus a way to report a problem and reach someone responsible for follow-up. A grey-market vial sold without clinical review leaves those questions open.
Those records do not settle the missing long-term evidence. A provider still weighs the treatment goal, current medicines, cancer and heart history, pituitary conditions, pregnancy and glucose problems. The blend's safety guide covers those uncertainties. If labs are considered, IGF-1, a growth signal measured in blood, needs the person's age and laboratory range for context.
At Promise, a licensed provider reviews every request and not everyone qualifies. The prescriber sets any dose and follow-up plan for the actual formulation.
Why tesamorelin comes into the comparison
Tesamorelin is another GHRH analogue, a molecule resembling the same hormone-release signal. It can be paired with ipamorelin, but swapping the GHRH molecule changes the evidence question.
The Egrifta WR label, which reads “Revised: 3/2025,” describes tesamorelin for excess abdominal fat in adults with HIV-associated lipodystrophy, abnormal fat distribution. Its indication does not transfer to a blend or establish general weight-loss benefits.
Compounded tesamorelin/ipamorelin is different from FDA-approved Egrifta WR: the compounded formulation is not FDA-approved. Tesamorelin's own clinical record cannot stand in for a trial of either ipamorelin combination.
What would change the next update
A trial of the actual pair could answer questions the separate studies leave open. The useful details would be the exact CJC-1295 form, route, patient group, comparison and outcomes measured. A study of hormone levels alone would still leave questions about how people feel and function.
For example, a recovery trial would need to measure function in people with a defined injury. A sleep trial would need a sleep outcome. A higher hormone result cannot answer either question on its own. The comparison group and length of follow-up would help show whether a change was meaningful and whether unwanted effects appeared later.
The same care applies to a new safety report. It matters which ingredient was given, how it was administered and whether other explanations were assessed. A report after a blend cannot automatically identify which of its two ingredients was responsible.
For the regulatory record, a newly dated FDA document matters more than a recirculated screenshot. For athletes, January 1 is when the 2027 list takes effect; a Therapeutic Use Exemption, formal permission for a medical need, is a separate decision. The next meaningful update needs to identify which of these questions actually changed.
